Treatment outcomes of overactive bladder with combined therapies of botulinum toxin injections and oral agents.
Botulinum toxin
Overactive bladder
Journal
International urogynecology journal
ISSN: 1433-3023
Titre abrégé: Int Urogynecol J
Pays: England
ID NLM: 101567041
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
15
10
2020
accepted:
04
01
2021
pubmed:
24
2
2021
medline:
25
2
2023
entrez:
23
2
2021
Statut:
ppublish
Résumé
Treatment options for refractory overactive bladder (OAB) following behavioral modifications and oral OAB medications remain limited. Up to 33% of women fail botulinum toxin injections (Amundsen et al. Eur Urol. 74(1):66-73, 7). This study evaluates the effectiveness of combining oral OAB agents with botulinum toxin in subjects who failed botulinum toxin therapy alone. This is a retrospective observational study. Eligible women were those who received botulinum toxin injections for OAB between 2013 and 2018 at one academic institution. Women were given the option of oral medications as add-back therapy following failed treatment with botulinum toxin alone. Treatment response was a subjective outcome, with subjects reporting being satisfied or unsatisfied. The primary outcome was the proportion of subjects who achieved satisfactory treatment response with the combination of oral OAB medications and botulinum toxin injections. A subanalysis was performed to further investigate any risk factors associated with poor response to combination treatment. Variables were analyzed using chi-squared or Fisher's exact test and Student's t-test or Mann-Whitney U when appropriate. A total of 107 charts were reviewed. Forty-five (48%) women failed botulinum toxin alone as a treatment; 26 (29%) elected to try one or more oral OAB medications. Of the 26 women who received the combination treatment, 17 (65%) reported satisfaction and 9 (35%) remained unsatisfied. Risk factors associated with treatment failure were not identified. This is an initial report on adding back oral OAB meds to patients who have failed botulinum toxin injections suggesting there may be a role for add-back oral OAB medications.
Identifiants
pubmed: 33620537
doi: 10.1007/s00192-021-04676-3
pii: 10.1007/s00192-021-04676-3
doi:
Substances chimiques
Botulinum Toxins
EC 3.4.24.69
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2803-2806Informations de copyright
© 2021. The International Urogynecological Association.
Références
Kirby A, Park S, et al. Practice patterns for women with overactive bladder syndrome: time between medications and third-line treatments. Female Pelvic Med Reconstr Surg. 2020;26(7):431–6.
doi: 10.1097/SPV.0000000000000811
Robinson D, Giarenis I, Cardozo L. The management of overactive bladder refractory to medical therapy. Maturitas. 2013;75(1):101–4. https://doi.org/10.1016/j.maturitas.2013.01.013 .
doi: 10.1016/j.maturitas.2013.01.013
pubmed: 23415926
AUA/SUFU Guideline: Published 2012; Amended 2014, 2019 Endorsed by the American Urogynecologic Society (AUGS) https://www.auanet.org/guidelines/overactive-bladder-(oab)-guideline . Accessed Oct 2020
White N, Iglesia CB. Overactive bladder. Obstet Gynecol Clin N Am. 2016;43(1):59–68.
doi: 10.1016/j.ogc.2015.10.002
Raju R, Linder BJ. Evaluation and treatment of overactive bladder in women. Mayo Clin Proc. 2020;95(2):370–7.
doi: 10.1016/j.mayocp.2019.11.024
Linder BJ, Gebhart JB, Elliott DS, Van Houten HK, Sangaralingham LR, Habermann EB. National patterns of filled prescriptions and third-line treatment utilization for privately insured women with overactive bladder. Female Pelvic Med Reconstr Surg. https://doi.org/10.1097/SPV.0000000000000744 .
Amundsen CL, Komesu YM, Chermansky C, et al. Two-year outcomes of sacral neuromodulation versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial. Eur Urol. 2018;74(1):66–73.
doi: 10.1016/j.eururo.2018.02.011
Tutolo M, Ammirati E, Heesakkers J, et al. Efficacy and safety of sacral and percutaneous Tibial neuromodulation in non-neurogenic lower urinary tract dysfunction and chronic pelvic pain: a systematic review of the literature. Eur Urol. 2018;73(3):406–18.
doi: 10.1016/j.eururo.2017.11.002
Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22.
doi: 10.1016/j.juro.2010.08.021
Elbaset M, Taha, DE, El-Hefnawy AS, Zahran MH, & Shokeir A, et al. Assessment of anticholinergic use after fading of BTX-A effects in refractory idiopathic overactive bladder: A prospective blinded randomized trial. Int Neurourol J. 2019;23(3):240–248. (Korean Continence Society).
Tang DH, Colayco DC, Khalaf KM, Piercy J, Patel V, Globe D, et al. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder. BJUI. 2014;113(3):484–91.
doi: 10.1111/bju.12505
Vrijens D, Drossaerts J, van Koeveringe G, Van Kerrebroeck P, van Os J, Leue C. Affective symptoms and the overactive bladder - a systematic review. J Psychosom Res. 2015;78(2):95–108.
doi: 10.1016/j.jpsychores.2014.11.019
Moskowitz D, Adelstein SA, Lucioni A, Lee UJ, Kobashi KC. Use of third line therapy for Overactive Bladder in a practice with multiple subspecialty providers-are we doing enough? J Urol. 2018;199(3):779–84.
doi: 10.1016/j.juro.2017.09.102